Jade Biosciences
JBIO
80 hedge funds and large institutions have $45.1M invested in Jade Biosciences in 2024 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 30 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 10
88% more call options, than puts
Call options by funds: $516K | Put options by funds: $275K
10% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 30
4% more funds holding
Funds holding: 77 → 80 (+3)
0.22% less ownership
Funds ownership: 2.92% → 2.69% (-0.22%)
95% less capital invested
Capital invested by funds: $841M → $45.1M (-$796M)
100% less funds holding in top 10
Funds holding in top 10: 6 → 0 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$26.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.6M |
| 3 |
AG
Artal Group
Luxembourg
|
+$15.3M |
| 4 |
Millennium Management
New York
|
+$11M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$35.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$31.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$26.2M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$23.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$19.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
D.E. Shaw & Co
New York
| – | -$511K | -493 | Closed |
|
|
TPC
102
Takeda Pharmaceutical Company
Tokyo,
Japan
| – | -$402K | -388 | Closed |
|
|
PP
103
PDT Partners
New York
| – | -$375K | -362 | Closed |
|
|
JF
104
Jump Financial
Chicago,
Illinois
| – | -$284K | -274 | Closed |
|
105
Renaissance Technologies
New York
| – | -$222K | -214 | Closed |
|
106
American Century Companies
Kansas City,
Missouri
| – | -$211K | -204 | Closed |
|
|
AIG
107
American International Group
New York
| – | -$163K | -157 | Closed |
|
|
MIM
108
MetLife Investment Management
Whippany,
New Jersey
| – | -$98.8K | -149 | Closed |
|
|
EC
109
EntryPoint Capital
New York
| – | -$92.4K | -89 | Closed |
|
|
MLICM
110
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$20.7K | -20 | Closed |
|
|
AWM
111
Avior Wealth Management
Omaha,
Nebraska
| – | -$59 | – | – |
|
112
Russell Investments Group
London,
United Kingdom
| – | -$207 | – | – |
|
113
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$1.99K | +3 | New |
|
JBIO Hedge Fund Activity: Q2 2024 in Review
80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q2 2024, worth a combined $45.1M — down 95% from $841M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new JBIO positions and 30 closed out — a net gain of 3 holders — while 28 added to existing stakes and 10 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $26.7M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $35.6M sold.
- 80 institutional investors held Jade Biosciences (JBIO) as of Q2 2024, up from 77 in Q1 2024.
- Funds reported $45.1M of Jade Biosciences stock for Q2 2024, down 95% quarter-over-quarter.
- 33 funds opened new Jade Biosciences positions in Q2 2024 and 30 closed out, a net change of +3 holders.
- The largest Jade Biosciences buyer in Q2 2024 was Deerfield Management, an estimated $26.7M added.
- The largest Jade Biosciences seller in Q2 2024 was Frazier Life Sciences Management, an estimated $35.6M sold.
Based on aggregated 13F filings for Q2 2024.